Rating Change
Stifel reiterated its Buy rating on Incyte Corporation (NASDAQ:INCY) on October 05, 2026.
Stifel reiterated its Buy rating on Incyte Corporation (NASDAQ:INCY) on October 05, 2026.

At publication ·
Incyte Corporation (NASDAQ:INCY) · reiterate
At a glance
Stifel reiterated its Buy rating on Incyte Corporation (NASDAQ:INCY) on October 05, 2026.
Incyte Corporation operates in the Healthcare sector. The stock currently trades at $114.13 with a market capitalization of $18.9B. The stock has gained 12.3% over the past 52 weeks.
Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Incyte Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | Stifel | Buy | N/A |
| Oct 01, 2026 | Wells Fargo | Equal-Weight | N/A |
| Sep 28, 2026 | JP Morgan | Neutral | N/A |
| Sep 28, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 22, 2026 | RBC Capital | Sector Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View INCY Stock Page
A rating of Buy from Stifel reflects the analyst's outlook on Incyte Corporation (NASDAQ:INCY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INCY forecast page.
Current market data
NASDAQ · INCY
$112.73
Down: -$1.40 · -1.23%
Live quote updated
Keep reading
analyst ·
analyst ·
institutional ·
analyst ·